Pharmaceutical Research

, Volume 22, Issue 11, pp 1898–1905 | Cite as

Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice

  • Manuela Pereira de Oliveira
  • Emmanuel Garcion
  • Nicolas Venisse
  • Jean-Pierre Benoît
  • William Couet
  • Jean-Christophe Olivier
Research Paper


Due to protease inhibitor (PI) efflux transport by P-glycoprotein (P-gp), insufficient PI concentrations result in low ongoing HIV replication in the so-called virus sanctuaries (brain and testes). The aim of the present study was to evaluate indinavir-loaded nanocapsules (Ind-LNC) including Solutol® HS15, an excipient reported to possess in vitro P-gp inhibiting properties, as a means to improve indinavir distribution into brain and testes of mice.


Normal mdr1a (+/+) or P-gp-deficient mdr1a (−/−) CF-1 mice were dosed with Ind-LNC (10 mg indinavir/kg, i.v.). At 30 min postadministration, indinavir was determined in plasma, brain, testes, as well as in kidneys, liver, and heart by LC-MS/MS, and tissue/plasma concentration ratios were calculated. Results were compared with those of control groups that received an indinavir solution (Ind-Sol).


Using Ind-Sol, ratios were 21.3- and 3.3-fold higher in brains and testes of mdr1a (−/−) mice than of mdr1a (+/+) mice, respectively, whereas in the other organs ratios were not significantly different between the two substrains. When Ind-LNC was used, a similar [mdr1a (−/−) vs. mdr1a (+/+) mice] trend was observed. Moreover, ratios were found to be significantly increased (1.9-fold increase in average) in most organs (brain and testes in particular) with Ind-LNC compared to Ind-Sol, regardless of the substrain used.


In agreement with previous works, P-gp governs at least in part indinavir uptake into brain and testes. LNC formulation increased indinavir uptake in brain and testes by mechanisms other than, or additional to, P-gp inhibition.

Key Words

CF-1 mice indinavir P-glycoprotein solid lipid nanocapsule Solutol® HS15 



indinavir-loaded lipid nanocapsules


indinavir solution


lipid nanocapsule



We are grateful for the excellent technical assistance of Mrs. Isabelle Lamarche.


  1. 1.
    Lewis, J. S., Terriff, C. M., Coulston, D. R., Garrison, M. W. 1997Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virusClin. Ther.19187214CrossRefPubMedGoogle Scholar
  2. 2.
    Pomerantz, R. J. 2002Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradicationClin. Infect. Dis.349197CrossRefPubMedGoogle Scholar
  3. 3.
    Chun, T. W., Fauci, A. S. 1999Latent reservoirs of HIV: obstacles to the eradication of virusProc. Natl. Acad. Sci. USA961095810961CrossRefPubMedGoogle Scholar
  4. 4.
    Kolson, D. L., Lavi, E., Gonzalvez-Scarano, F. 1998The effects of human immunodeficiency virus in the central nervous systemAdv. Virus Res.50147PubMedGoogle Scholar
  5. 5.
    Zhang, H., Dornadula, G., Beaumont, M., Livornese, L. J., Uitert, B., Henning, K., Pomerantz, R. J. 1998Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapyN. Engl. J. Med.33918031809CrossRefPubMedGoogle Scholar
  6. 6.
    Kepler, T. B., Perelson, A. S. 1998Drug concentration heterogeneity facilitates the evolution of drug resistanceProc. Natl. Acad. Sci. USA951151411519CrossRefPubMedGoogle Scholar
  7. 7.
    Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., Willingham, M. C. 1987Cellular localization of the multidrug resistance gene product in normal human tissuesProc. Natl. Acad. Sci. USA8477357738PubMedGoogle Scholar
  8. 8.
    Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., Bertino, J. R. 1989Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood brain barrier sitesProc. Natl. Acad. Sci. USA86695698PubMedGoogle Scholar
  9. 9.
    Lange, E. C. 1989Potential role of ABC transporters as a detoxification system at the blood–CSF barrierAdv. Drug. Deliv. Rev.5617931809CrossRefGoogle Scholar
  10. 10.
    Melaine, N., Lienard, M. O., Dorval, I., Goascogne, C., Lejeune, H., Jegou, B. 2002Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig and humanBiol. Reprod.6716991707CrossRefPubMedGoogle Scholar
  11. 11.
    Kim, R. B., Fromm, M. F., Wandel, C., Wood, A. J., Roden, D. M., Wilkinson, G. R. 1998The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV protease inhibitorsJ. Clin. Invest.101289294PubMedGoogle Scholar
  12. 12.
    Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J., Wilkinson, G. R., Kim, R. B. 2000Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testesDrug Metab. Dispos.28655660PubMedGoogle Scholar
  13. 13.
    Lin, J. H. 2004How significant is the role of P-glycoprotein in drug absorption and brain uptake?Drugs Today (Barc.)40522CrossRefGoogle Scholar
  14. 14.
    Bender, A. R., Briesen, H., Kreuter, J., Duncan, I. B., Rubsamen-Waigmann, H. 1996Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitroAntimicrob. Agents Chemother.4014671471PubMedGoogle Scholar
  15. 15.
    Gagne, J. F., Desormeaux, A., Perron, S., Tremblay, M. J., Bergeron, M. G. 2002Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomesBiochim. Biophys. Acta1558198210PubMedGoogle Scholar
  16. 16.
    B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, J. Richard, J. P. Benoit. A novel phase inversion-based process for the preparation of lipidic nanocarriers, 2000. Patent FR 0002688.Google Scholar
  17. 17.
    Cahouet, A., Denizot, B., Hindre, F., Passirani, C., Heurtault, B., Moreau, M., Jeune, J., Benoit, J. P. 2002Biodistribution of dual radiolabeled lipidic nanocapsules in the rat using scintigraphy and gamma countingInt. J. Pharm.242367371CrossRefPubMedGoogle Scholar
  18. 18.
    Coon, J. S., Knudson, W., Clodfelter, K., Lu, B., Weinstein, R. S. 1991Solutol HS 15, non toxic polyethylene esters of 12-hydroxystearic acid reverses multidrug resistanceCancer Res.51897902PubMedGoogle Scholar
  19. 19.
    Buckingham, L. E., Balasubramanian, M., Safa, A. R., Shah, H., Komarov, P., Emanuele, R. M., Coon, J. S. 1996Reversal of multi-drug resistance in vitro by fatty acid–PEG–fatty acid diesterInt. J. Cancer657479CrossRefPubMedGoogle Scholar
  20. 20.
    Bravo Gonzalez, R. C., Huwyler, J., Boess, F., Walter, I., Bittner, B. 2004In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolamBiopharm. Drug Dispos.253749CrossRefPubMedGoogle Scholar
  21. 21.
    Li, L. Y., Amidon, G. L., Kim, J. S., Heimbach, T., Kesisoglou, F., Topliss, J. T., Fleisher, D. 2002Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in ratJ. Pharmacol. Exp. Ther.301586593CrossRefPubMedGoogle Scholar
  22. 22.
    Tse, F. L. S. 1995

    Pharmacokinetics in drug discovery and development: nonclinical studies

    Welling, P. G.Tse, F. L. S. eds. Pharmacokinetics: Regulatory, Industrial, Academic Perspectives2Marcel DekkerNew York281334
    Google Scholar
  23. 23.
    Wu, E. Y., Wilkinson, J. M., Naret, D. G., Daniels, V. L., Williams, L. J., Khalil, D. A., Shetty, B. V. 1997High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasmaJ. Chromatogr. B Biomed. Sci. Appl.695373380CrossRefPubMedGoogle Scholar
  24. 24.
    Heeswijk, R. P., Hoetelmans, R. M., Harms, R., Meenhorst, P. L., Mulder, J. W., Lange, J. M., Beijnen, J. H. 1998Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detectionJ. Chromatogr. B Biomed. Sci. Appl.719159168PubMedGoogle Scholar
  25. 25.
    Chi, J., Jayewardene, A. L., Stone, J. A., Motoya, T., Aweeka, F. T. 2002Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MSJ. Pharm. Biomed. Anal.30675684CrossRefPubMedGoogle Scholar
  26. 26.
    Croop, J. M., Raymond, M., Haber, D., Devault, A., Arceci, R. J., Gros, P., Housman, D. E. 1989The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissuesMol. Cell Biol.913461350PubMedGoogle Scholar
  27. 27.
    Pippert, T. R., Umbenhauer, D. R. 2001The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a geneJ. Biochem. Mol. Toxicol.158389CrossRefPubMedGoogle Scholar
  28. 28.
    Schuetz, E. G., Umbenhauer, D. R., Yasuda, K., Brimer, C., Nguyen, L., Relling, M. V., Schuetz, J. D., Schinckel, A. H. 2000Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genesMol. Pharmacol.57188197PubMedGoogle Scholar
  29. 29.
    Lankas, G. R., Cartwright, M. E., Umbenhauer, D. 1997P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances ivermectin-induced neurotoxicityToxicol. Appl. Pharmacol.143357365CrossRefPubMedGoogle Scholar
  30. 30.
    Bush, J. A., Li, G. 2002Regulation of the mdr1 isoforms in a p53-deficient mouse modelCarcinogenesis2316031607CrossRefPubMedGoogle Scholar
  31. 31.
    Mizuno, N., Niwa, T., Yotsumoto, Y., Sugiyama, Y. 2003Impact of drug transporter studies on drug discovery and developmentPharmacol. Rev.55425461CrossRefPubMedGoogle Scholar
  32. 32.
    Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., Deemter, L., Smit, J. J., Valk, M. A., Voordouw, A. C., Spits, H., Tellingen, O., Zijlmans, J. M., Fibbe, W. E., Borst, P. 1997Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteinsProc. Natl. Acad. Sci. USA9440284033CrossRefPubMedGoogle Scholar
  33. 33.
    Holash, J. A., Harik, S. I., Perry, G., Stewart, P. A. 1993Barrier properties of testis microvesselsProc. Natl. Acad. Sci. USA901106911073PubMedGoogle Scholar
  34. 34.
    Asperen, J., Tellingen, O., Tijssen, F., Schinkel, A. H., Beijnen, J. H. 1999Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoproteinBr. J. Cancer79108113PubMedGoogle Scholar
  35. 35.
    Jodoin, J., Demeule, M., Fenart, L., Cecchelli, R., Farmer, S., Linton, K. J., Higgins, C. F., Beliveau, R. 2003P-glycoprotein in blood–brain barrier endothelial cells: interaction and oligomerization with caveolinsJ. Neurochem.8710101023CrossRefPubMedGoogle Scholar
  36. 36.
    Huisman, M. T., Smit, J. W., Crommentuyn, K. M., Zelcer, N., Wiltshire, H. R., Beijnen, J. H., Schinkel, A. H. 2002Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors and transport can enhanced by other drugsAIDS1622952301CrossRefPubMedGoogle Scholar
  37. 37.
    Rosati, A., Maniori, S., Decorti, G., Candussio, L., Giraldi, T., Bartoli, F. 2003Physiological regulation of P-glycoprotein MRP1, MRP2 and cytochrome P 450 3A2 during rat ontogenyDev. Growth Differ.45377387CrossRefPubMedGoogle Scholar
  38. 38.
    Chong, A. S., Markham, P. N., Gebel, H. M., Bines, S. D., Coon, J. S. 1993Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cellsCancer Immunol. Immunother.36133139CrossRefPubMedGoogle Scholar
  39. 39.
    Buszello, K., Harnisch, S., Muller, R. H., Muller, B. W. 2000The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS15Eur. J. Pharm. Biopharm.49143149CrossRefPubMedGoogle Scholar
  40. 40.
    Woodburn, K., Sykes, E., Kessel, D. 1995Interactions of Solutol HS 15 and Cremophor EL with plasma lipoproteinsInt. J. Biochem. Cell. Biol.27693699CrossRefPubMedGoogle Scholar
  41. 41.
    Buckingham, L. E., Balasubramanian, M., Emanuele, R. M., Clodfelter, K. E., Coon, J. S. 1995Comparison of Solutol HS 15, Cremophor EL and novel ethoxylated fatty acid surfactants as multidrug resistance modification agentsInt. J. Cancer62436442PubMedGoogle Scholar
  42. 42.
    Komarov, P. G., Shtil, A. A., Buckingham, L. E., Balasubramanian, M., Piraner, O., Emanuele, R. M., Roninson, I. B., Coon, J. S. 1996Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid–polyethylene glycol–fatty acid diesters, novel inhibitors of P-glycoprotein functionInt. J. Cancer68245250CrossRefPubMedGoogle Scholar
  43. 43.
    Bittner, B., Gonzalez, R. C., Walter, I., Kapps, M., Huwyler, J. 2003Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar ratsBiopharm. Drug Dispos.24173181CrossRefPubMedGoogle Scholar
  44. 44.
    Bittner, B., Gonzalez, R. C., Isel, H., Flament, C. 2003Impact of Solutol HS 15 on the pharmacokinetic behavior of midazolam upon intravenous administration to male Wistar ratsEur. J. Pharm. Biopharm.56143146CrossRefPubMedGoogle Scholar
  45. 45.
    Lockman, P. R., Koziara, J., Roder, K. E., Paulson, J., Abbruscato, T. J., Mumper, R. J., Allen, D. D. 2003In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticlesPharm. Res.56705713CrossRefGoogle Scholar
  46. 46.
    Vonarbourg, A., Saulnier, P., Passirani, C., Benoit, J. P. 2005Electrokinetic properties of noncharged lipid nanocapsules: influence of the dipolar distribution at the interfaceElectrophoresis2620662075CrossRefPubMedGoogle Scholar
  47. 47.
    Dudeja, P. K., Anderson, K. M., Harris, J. S., Buckingham, L., Coon, J. S. 1995Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidityArch Biochem. Biophys.319309315CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Manuela Pereira de Oliveira
    • 1
  • Emmanuel Garcion
    • 2
  • Nicolas Venisse
    • 1
    • 3
  • Jean-Pierre Benoît
    • 2
  • William Couet
    • 1
    • 3
  • Jean-Christophe Olivier
    • 1
  1. 1.Faculté de Médecine & PharmacieEA3809 “Pharmacologie des Médicaments Anti-Infectieux”, Pôle Biologie-SantéPoitiers CEDEXFrance
  2. 2.Inserm-U 646 Bâtiment IBTAngersFrance
  3. 3.Faculté de Médecine & Pharmacie, Laboratoire de PharmacocinétiqueCentre Hospitalo-Universitaire de Poitiers, Pôle Biologie-SantéPoitiers CEDEXFrance

Personalised recommendations